510(k) · Cleared
ClearedGSP Neonatal 17A-OH-Progesterone Kit Model: 3305-001U
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Wallac OY · JLX Radioimmunoassay, 17-Hydroxyprogesterone
Cleared on Jul 23, 2010 as substantially equivalent to K081922 (Wallac OY, 2009) after a 135-day review. Its family tree reaches back 3 generations to 1991.
- Decided
- Jul 23, 2010
- Review
- 135 days
- Class
- Class I
- Product code
- JLX
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 3 generations to K912026 (1991). 4 ancestors in all. No later device cites it as a predicate yet.
- Root · 3 generations backK912026 Delfia (R) 17 -OH-Progesteron KitPharmacia Diagnostics, Inc. · 1991
- 2 generations backK042425 Autodelfia Neonatal 17A-OH-Progesterone KitWallac OY · 2004
- 1 generation backK081922 Autodelfia Neonatal 17A-OH-Progesterone KitWallac OY · 2009
- This deviceK100682 GSP Neonatal 17A-OH-Progesterone Kit Model: 3305-001UWallac OY · 2010
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −3 | K912026 | Delfia (R) 17 -OH-Progesteron Kit | Pharmacia Diagnostics, Inc. | 1991 | — |
| −2 | K042425 | Autodelfia Neonatal 17A-OH-Progesterone Kit | Wallac OY | 2004 | — |
| −1 | K081922 | Autodelfia Neonatal 17A-OH-Progesterone Kit | Wallac OY | 2009 | — |
| 0 (this device) | K100682 | GSP Neonatal 17A-OH-Progesterone Kit Model: 3305-001U | Wallac OY | 2010 | — |
Other ancestors by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 1994 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in JLX? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
- Candidate predicates for a device like this, rankedin the report
- Recall history across each candidate’s familyin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K081922 | Autodelfia Neonatal 17A-OH-Progesterone KitSummary page 1…esterone Product Code: JLX Predicate Device: AutoDELFIA® Neonatal 17u.-OH-progesterone kit, 510(k) Number (K08 1922) Device Description: The GSP Neonatal 17a-OH-progesterone (I17-OHP) assay is a solid p… | 2009 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 19 years and passes through 2 companies; a new generation was cleared every 4.5 years on median.
- 1 of the 4 ancestors has a recall of any class.
How does its category compare?
All JLX devicesJLX Radioimmunoassay, 17-Hydroxyprogesterone: FDA decisions, review times, recalls and adverse event reports over 20 years. 2010, this device’s year, is highlighted.
FDA decisions per year · JLX
1in 2010
2026 to Oct 25, outlined.
Median 510(k) review, days · JLX
Too few JLX 510(k)s in any year since 2007 to give a median.
Recalls per year · JLX
1in 2024
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · JLX
1in 2021
MAUDE reports naming product code JLX, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 1 | — | 0 | 0 |
| 2008 | 1 | — | 0 | 1 |
| 2009 | 1 | — | 0 | 1 |
| 2010 | 1 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 0 | — | 0 | 1 |
| 2015 | 0 | — | 0 | 2 |
| 2016 | 0 | — | 0 | 0 |
| 2017 | 0 | — | 0 | 0 |
| 2018 | 0 | — | 0 | 0 |
| 2019 | 0 | — | 0 | 0 |
| 2020 | 0 | — | 0 | 0 |
| 2021 | 0 | — | 0 | 1 |
| 2022 | 0 | — | 0 | 0 |
| 2023 | 0 | — | 0 | 0 |
| 2024 | 0 | — | 1 | 0 |
| 2025 | 0 | — | 0 | 0 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
The GSP Neonatal 17a-OH-progesterone kit is intended for the quantitative determination of human 17a,-OH-progesterone in blood-specimens dried on filter paper as an aid in screening newborns for congenital adrenal hyperplasia (CAH) using the GSPTM instrument.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K100682 · printed Nov 6, 2026
Cite this page
510(k) Report. “K100682: GSP Neonatal 17A-OH-Progesterone Kit Model: 3305-001U.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K100682
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026